Treating HIV-Positive/Non-AIDS Patients for Community-Acquired Pneumonia with ART by Cillóniz, Catia et al.
AUTHOR'S PROOF
U
N
C
O
R
R
EC
TE
D
PR
O
O
F
1
2
3 RESPIRATORY INFECTIONS (F ARNOLD, SECTION EDITOR)
4
5 Treating HIV-Positive/Non-AIDS Patients for Community-Acquired
6 Pneumonia with ART
7 Catia Cillóniz1 & Antonella Ielpo2 & Antoni Torres1
8
9
10 # Springer Science+Business Media, LLC, part of Springer Nature 2018
11 Abstract
12 Purpose of Review This article reviews the most recent publications on community-acquired pneumonia (CAP) in the HIV-
13 infected population on antiretroviral therapy (ART), focusing on epidemiology, prognostic factors, etiology, and antimicrobial
14 therapy. The data discussed here were mainly obtained from a non-systematic review usingMedline and references from relevant
15 articles.
16 Recent Findings CAP remains a major cause of morbidity and mortality among HIV-infected patients and incurs high health
17 costs despite the introduction of ART.
18 Summary HIV-infected patients are generally known to be more susceptible to bacterial pneumonia. Streptococcus pneumoniae
19 is the most frequently reported pathogen in HIV-infected patients on ART, who present a higher rate of bacteremia than non-HIV-
20 infected patients. Several studies have also examined microbial etiology and prognostic factors of CAP in HIV-infected patients
21 on ART. Despite the high rate of bacterial pneumonia in these patients, mortality rates are not higher than in patients without HIV
22 infection.
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24
25 Introduction
26 According to the World Health Organization (WHO), at the
27 end of 2016, there were approximately 36.7 million people
28 living with human immunodeficiency virus (HIV): 25.6 mil-
29 lion in Africa, 3.5 million in Southeast Asia, 3.3 million in the
30 Americas, 2.4 million in Europe, 1.5 million in the Western
31 Pacific, and 360,000 in the Eastern Mediterranean. By mid-
322017, approximately 20.9 million people living with HIV
33were receiving active antiretroviral therapy (ART), including
34seven out of every 10 pregnant women living with HIV [1]. In
352016, 1.8 million people became newly infected with HIV [2].
36The introduction of active ART has changed the epidemiology
37of HIV infection and acquired immune deficiency syndrome
38(AIDS) worldwide [3, 4]. However, community-acquired
39pneumonia (CAP) remains a frequent cause of morbidity
40and mortality among HIV-infected patients on ART, and in-
41curs high health costs [4–6]. Some associated factors that con-
42tribute to the high incidence of CAP in HIV-infected patients
43on ART are active or passive smoking, alcohol abuse, and
44intravenous drug use [7••].
45Although ART reduces viral replication and systemic in-
46flammation and improves immune response, the risk of pneu-
47monia remains high in these patients in part because they
48present altered immunity and their immune activation persists
49even when they receive therapy [6]. The incidence of CAP in
50HIV-infected patients on ART is reported to be between 2.5
51and 8 cases per 1000 patients per year [8]. The risk of CAP in
52HIV-infected patients on ART and the probability of mixed
53infections or pneumonia caused by intracellular pathogens is
54inversely associated with the CD4 cell count [6, 7••, 9].
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55 Mortality in HIV-infected patients onARTwith CAP ranges
56 from 6 to 9% [9, 10]; in patients with severe CAP, however,
57 it may be above 30% [11, 12]. Streptococcus pneumoniae
58 (pneumococcus) is themain pathogen involved in CAP in both
59 HIV-infected patients on ART and the general population
60 [9, 13••, 14•]. HIV is a known risk factor for invasive pneumo-
61 coccal disease (IPD); even when receiving ART, HIV-infected
62 patients on ART had a 20-fold increased risk of IPD [7••,
63 15, 16].
64 Vaccination (pneumococcal conjugate [PCV13] and poly-
65 saccharide vaccines [PPV23]) represents one of the most im-
66 portant preventive strategies for CAP in HIV-infected patients
67 on ART [17]. Implementation of programs to help patients
68 comply with ART and early diagnosis of suspected HIV-
69 infected patients are key measures for improving CAP
70 management.
71 Global Epidemiology of CAP in HIV-Infected
72 Adult Patients
73 The introduction of ART changed the global epidemiology of
74 pulmonary infection in the HIV-infected population [18] by
75 reducing the incidence of opportunistic pulmonary infections.
76 In high-income countries, such as Europe and the USA, bac-
77 terial pneumonia (especially pneumococcal pneumonia) is the
78 predominant lung disease in the HIV-infected population on
79 ART [4, 9].
80 A Brazilian study of CAP in HIV-infected adult patients
81 receiving ART for at least 60 days reported an incidence of
82 pneumonia of 3.07 cases per 100 persons-years. Viral load and
83 CD4 cell counts were identified as predictive factors for pneu-
84 monia. Uncontrolled HIV infection (detectable viral load)
85 doubled the risk for pneumonia, while time-updated increases
86 in CD4 cell counts represented a protective factor [19].
87 Analyzing more than 10,000 patients in 34 countries, the
88 EuroSIDA cohort study reported an incidence of 0.53 cases
89 per 100 persons-year and identified low CD4 cell count (200–
90 349 cells/μl), current smoking, and higher viral load as risk
91 factors for pneumonia [20]. Similarly, Mussini et al. [21] re-
92 ported an incidence of 0.56 cases of pneumonia per 100
93 persons-year and found the probabilities of first episode of
94 bacterial pneumonia at 3, 5, 10, and 14 years after ART initi-
95 ation to be 2%, 2.9%, 4.3%, and 5.7% respectively. The fac-
96 tors associated with the first episode of bacterial pneumonia
97 were low nadir CD4+, low current CD4, high CD8+, low he-
98 moglobin, unfavorable virological outcome, older age, male
99 gender, non-Italian nationality, smoking, and longer time to
100 ART initiation.
101 In a 10-year study of survival of HIV-infected patients ad-
102 mitted to the ICU in the UK between 1999 and 2009 [22], it
103 was observed that respiratory disease remains the main cause
104 of ICU admission. The proportion of patients on ART prior to
105ICU admission increased from 37% in the early period (1999–
1062005) to 60% in the late period (2006–2009). In patients new-
107ly diagnosed with HIV, the rates of survival to ICU and hos-
108pital discharge were 69% and 57% respectively. In patients
109with known HIV diagnosis, survival to ICU and hospital dis-
110charge was 80% and 74% respectively.
111Another UK study [23] of the implementation of automated
112HIV testing for pneumonia patients admitted to the ICU re-
113ported that prior to this measure, the HIV testing rate in pa-
114tients with pneumonia within 2 weeks of admission was 29%.
115After the implementation of automated HIV testing to all ad-
116mitted patients, 80% of ICU patients with pneumonia were
117tested for HIV infection within 48 h and 73% with 24 h.
118Adopting universal testing for HIV in patients with pneumo-
119nia admitted to ICU is mandatory in order to reduce morbidity
120and mortality.
121Microbial Etiology of CAP in HIV-Infected
122Patients
123Despite advances in microbiological tests, microbial diagnosis
124is achieved in only 40–50% of CAP cases [9, 13••]. The bac-
125terial etiology of pneumonia is similar in HIV-infected pa-
126tients on ART and in the uninfected population [24, 25].
127Factors that have an impact on microbial etiology in CAP
128are the characteristics of the population, the geographical area
129(developed or developing countries), and the methodology
130applied to microbial diagnosis [6, 26].
131A recent prospective observational study of 331 adult CAP
132cases in HIV-infected patients from Spain [13••] described the
133microbial etiology in this population. The most frequently
134detected microorganisms were S. pneumoniae (30%),
135P. jirovecii (13%), mixed etiology (11%), respiratory viruses
136(5%), Haemophilus influenzae (2%), Staphylococcus aureus
137(2%), and Legionella pneumophila (1%). S. pneumoniae was
138the most frequent microorganism in the group with a CD4+
139cell count of ≥ 200 cell/mm3 and P. jirovecii in the group of
140patients with a CD4+ cell count of < 200 cells/mm3 and in
141patients with HIV-RNA ≥ 200 copies/mL. The authors also
142reported that ≤ 5 days of symptoms (OR 2.6, 95% CI 1.5–
1434.4), C-reactive protein level ≥ 22 mg/dL (OR 4.3, 95% CI
1442.3–8.2), and hepatitis C-virus co-infection (OR 2.3, 95% CI
1451.4–3.9) were predictors of bacterial CAP, whereas a WBC
146count ≤ 4000 × 109 cells/L (OR 3.7, 95% CI 1.2–11.5), LDH
147≥598 U/L (OR 12.9, 95% CI 4.2–39.7), and multilobar infil-
148tration (OR 5.8, 95% CI 1.9–19.5) were predictors of
149P. jirovecii. In that study, HIV infection had been diagnosed
150prior to hospital admission in 83% of patients, and 51% of
151patients were on ART; the other 17% were diagnosed with
152HIV infection during the pneumonia episode (Fig. 1).
153Pneumococcal pneumonia in HIV-infected patients fre-
154quently presents with bacteremia and invasive pneumonia
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155 [7••, 9]. In an earlier Spanish study of the microbial etiology of
156 CAP in HIV-infected patients, 15% of the study population
157 presented bacteremia, and pneumococcus was the main path-
158 ogen involved [13••]. In a study of 129 HIV-infected adult
159 patients with CAP, the factors that predicted bacteremia were
160 positive urinary antigen detection and the absence of ART
161 [27].
162 Pseudomonas aeruginosa is also a cause of pneumonia in
163 HIV-infected patients and is reported in fewer than 6% of CAP
164 cases [13••, 28]. Risk factors associated with P. aeruginosa
165 CAP in HIV-infected patients are previous antibiotic therapy,
166 neutropenia, and a low CD4 count [29].
167 Legionella pneumophila accounts for approximately 9% of
168 all adult HIV-associated pneumonias [10]. Other intracellular
169 pathogens causing CAP in HIV-infected patients include
170 Mycoplasma pneumoniae, Chlamydophila pneumoniae, and
171 Coxiella burnetii [30•]. A recent published case-control study
172 that compared the clinical presentation and outcomes (length
173 of hospital stay, ICU admission, and 30-day mortality) of
174 L. pneumophila pneumonia in HIV-infected patients (32
175 cases) and non-HIV-infected patients (96 controls) reported
176 that clinical presentation and outcomes in HIV-infected pa-
177 tients with Legionella pneumonia did not differ from patients
178 without HIV infection. The authors suggest that Legionella
179 infection affected with more frequently patients with correct
180 immunological status [31].
181 Severity of CAP and Site of Care
182 To determine the site of care, microbiological testing and the
183 choice of empiric antibiotic therapy, it is important to assess
184the pneumonia severity (Fig. 2). Severity scores for
185predicting short-term mortality have been developed in order
186to allow more objective decisions regarding hospitalization
187to be taken in the general population [32, 33]. The most
188frequent scores are the Pneumonia Severity Index (PSI), rec-
189ommended by the IDSA/ATS guidelines, and the CURB-65
190criteria recommended by the BTS guidelines. However, few
191studies have validated these severity scores in the HIV-
192infected population [10, 34]. In 2008, evaluating the PSI
193score in HIV-infected patients with CAP, Curran et al. [10]
194reported that it accurately predicted high-risk pneumonia and
195mortality. The authors suggested that the combination of
196CD4 cell count value and PSI risk class would help to iden-
197tify patients requiring hospitalization. More recently, a study
198investigating the use of CURB65 in HIV-infected patients
199reported that a higher CURB65 score and a CD4 count lower
200than 200 cells/mL were both associated with worse out-
201comes [34]. The authors concluded that the CURB65 score
202plus CD4 cell count could be used in HIV-infected patients
203with CAP.
204An interesting study assessing the predictive value of ana-
205lytical markers of full blood count that can be assessed in the
206emergency department in 160 HIV-infected patients with CAP
207(49% of them on ART) reported that higher red blood cell
208distribution width (RDW) (OR = 1.2, 95% CI 1.1–1.4, p =
2090.013) and a lower number of lymphocytes (OR 2.2, 95%
210CI 1.1–2.2, p = 0.035) were independent predictors of admis-
211sion to ICU in the multivariate analysis. The small number of
212cases analyzed was a limitation, but the combination of sever-
213ity scores and laboratory data such as RDWand lymphocytes
214may be a good predictor for prognosis in HIV-infected pa-
215tients with CAP [35].
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Fig. 1 Microbial etiology in HIV-
infected patients with CAP
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216 Microbial Diagnosis of CAP
217 Microbiological diagnosis of CAP continues to be based on
218 respiratory samples or blood culture. The most important ap-
219 plication of these methods is in the determination of antibiotic
220 susceptibility patterns that allow the selection of appropriate
221 antimicrobial therapy, which is an important factor for reduc-
222 ing mortality [36].
223In general, international guidelines recommend standard
224microbiological investigation [37, 38]. In the case of patients
225with low to mild pneumonia, microbiological diagnosis is
226optional. Extensive microbiological diagnosis is recommend-
227ed in cases of severe pneumonia or in cases that do not re-
228spond to empiric antibiotic therapy. However, if clinically in-
229dicated, an extensive microbiological diagnosis should be per-
230formed (Fig. 3).
Fig. 2 Clinical management CAP
in HIV-positive/non AIDS
patients
Fig. 3 International guideline recommendation for microbiological diagnostic test in CAP
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231 Blood cultures, sputum staining, sputum culture, and uri-
232 nary antigen testing for Legionella and pneumococcus should
233 be carried out in patients with severe CAP. Since influenza
234 viruses present in seasonal epidemics, rapid antigen or direct
235 fluorescent antibody testing is recommended to guide deci-
236 sions regarding antiviral therapy and may help to reduce the
237 use of antibacterial agents.
238 In recent years, the development and implementation of
239 molecular diagnostic tests for pneumonia have been major
240 advances in the microbiological diagnosis of respiratory path-
241 ogens. These technologies achieve rapid results (within 1–2 h)
242 and may be useful in the decision management of patients,
243 especially with regard to the early initiation of appropriate
244 antimicrobial therapy, a factor associated with mortality. The
245 rapid identification of antibiotic resistant pathogens is also
246 central to timely isolation of patients. However, the main lim-
247 itations of these technologies are their reduced ability to dif-
248 ferentiate between colonization and infection and their cost-
249 effectiveness [39].
250 Microbiome
251 A new challenge for microbiologists and clinicians has
252 arisen with the study of the pulmonary microbiome, which
253 has changed our current concept of pneumonia [40]. It is
254now known that the lungs are a dynamic microbiological
255ecosystem, and the new data show us that pneumonia
256involves a dysbiosis or alteration of the lung microbiome
257[39, 41•].
258An interesting study addressed by Iwai et al. [42••] com-
259pared oral and airway microbiota in patients with and with-
260out HIV-infection. The authors reported that HIV-infected
261patients with pneumonia have an increased abundance of
262phylogenetically distinct taxa, which included Firmicutes
263and Prevotellaceae compared with the presence of
264Proteobacteria-enriched communities in non-HIV-infected
265patients with pneumonia. A second interest study published
266by the same authors compared the lung microbiome between
267HIV-infected patients from Ugandan with pneumonia to
268pneumonia patients from San Francisco. The authors report-
269ed that the microbiome composition of lower airway of HIV-
270infected patients with pneumonia in Uganda was significant-
271ly different from those in San Francisco. The author sug-
272gested that these differences may be due to the clinical status,
273age, and/or pneumonia type across the geographically dis-
274tinct cohorts. The profile of microbiome in Uganda patients
275was enriched by Proteobacteria, being Pseudomonas
276aeruginosa the pathogen more frequently detected. On the
277other hand, lung microbiome in patients from San Francisco
278was enriched for Firmicutes and Actinobacteria [43].
Fig. 4 Empiric therapy for CAP in HIV-infected patients on ART
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279 The new investigations about the lung microbiome in HIV-
280 infected patients have provided novel insights and new knowl-
281 edge about the mechanisms of microbial pathogenesis in
282 pneumonia in this population.
283 Initial Empiric Therapy
284 When a HIV-infected patient with CAP is admitted to the
285 emergency department, clinicians should check the immuno-
286 logical status (CD4+ cell/count) and compliance with ART. IfQ2
287 patients are on ART and have a CD4 lymphocyte count of >
288 200 cells/mm3, the empiric antibiotic therapy for CAP is sim-
289 ilar to that administered in the general population [13••] and
290 complies with the international guidelines recommendations
291 for CAP [37, 38, 44, 45]. All patients will be visited within
292 30 days after hospital discharge and followed up on an outpa-
293 tient basis (Fig. 4).
294 Initial empiric therapy for CAP should be guided by the site
295 of care, age, previous use of antibiotics within the previous
29690 days, the presence of comorbidities (risk of resistant path-
297ogens), and drug intolerance.
298Empiric antiviral therapy for influenza may be necessary
299when the clinical and epidemiological criteria are met. Several
300studies reported that 1 to 6% of patients hospitalized with
301H1N1 were HIV-infected [46, 47]. In an American study,
302HIV patients with influenza experienced similar rates of ICU
303admission (29% vs. 34%) and mortality (13% vs. 13%) to
304those of non-HIV patients [46]. Ormsby et al. [48] suggested
305that the 2009 H1N1 infection was more severe in HIV-
306infected patients with late and advanced HIV disease than in
307well-controlled patients on ART.
308Two groups of antiviral drugs are currently available
309for influenza: M2-protein-inhibitors (amantadine and
310rimantadine) and neuraminidase inhibitors (zanamivir and
311oseltamivir). These antivirals should be administered with-
312in 48 h of symptom onset. In cases of severe pneumonia,
313medication is recommended even 48 h after symptom
314onset.
315Empiric antibiotic therapies recommended by international
316guidelines are summarized in Table 1 [37, 40, 41•, 44].
t1:1 Table 1 InternationalQ3 guidelines for the management and treatment for community-acquired pneumonia
t1:2 Pneumonia
severity
Low severity Moderate severity High severity
t1:3 GNAC
guidelines
• Moxifloxacin or levofloxacin:
5 to 7 days
• Amoxicillin or amoxicillin-clavulanate
(7 days) + macrolide (azithromycin
3–5 days or clarithromycin 7 days)
• Cefditoren is an alternative with is not
possible use amoxicillin or quinolones
• Third-generation (e.g., cefotaxime or
ceftriaxone) cephalosporin or
•Amoxicillin-clavulanate +macrolide
(azithromycin or clarithromycin)
• Moxifloxacin or fluoroquinolone
monotherapy
•Non-antipseudomonal cephalosporin in high dose
(ceftriaxone 2 g/24 h, cefotaxime 2 g/6–8 h) +
macrolide (azithromycin 500 mg/day or
clarithromycin 500 mg/12 h)
• Alternative: moxifloxacin (400 mg/24 h) or
levofloxacin (500 mg/12 h) instead of
macrolides
t1:4 BTS guidelines • CURB65 scores 0–1
• Treat with oral amoxicillin or
doxycycline or clarithromycin
• CURB65 score 2
• Treat with oral/intravenous
amoxicillin + clarithromycin or
doxycycline, moxifloxacin, or
levofloxacin
• CURB65 scores 3–5
• Treat with co-amoxiclav plus
clarithromycin/benzylpenicillin plus
levofloxacin or ciprofloxacin/or cephalosporin
plus clarithromycin
t1:5 ATS/IDSA
guidelines
• PSI OR CURB65 score to guide
outpatient treatment
• Treat with macrolide or doxycycline:
patients with low risk of drug-resistant
pneumococcus
• Treat with fluoroquinolone or ß-lactam
+ macrolide: patients with high risk of
drug-resistant pneumococcus
• Direct admission to ICU: septic shock
requiring vasopressor support and /or respiratory failure requiring
intubation and ventilation.
• ß-Lactam plus a macrolide or fluoroquinolone
t1:6 ERS/ESCMID
guidelines
• CURB65 to guide outpatient treatment
• Treatment:
*Aminopenicillin ± macrolide
*Aminopenicillin/b-lactamase inhibitor
± macrolide
*Non-antipseudomonal cephalosporin II
or III + macrolide
*Cefotaxime or ceftriaxone ± macrolide
*Penicillin G ± macrolide
• ICU admission: acute respiratory failure, severe sepsis, or septic shock and radiographic
extension of infiltrates/severely decompensated comorbidities
• No risk factors for P. aeruginosa: non-antipseudomonal cephalosporin III + macrolide or
non-antipseudomonal cephalosporin III + moxifloxacin or levofloxacin
• Risk factors for P. aeruginosa: antipseudomonal cephalosporin or acyl
ureidopenicillin/ß-lactamase inhibitor or carbapenem (meropenem preferred) plus
ciprofloxacin or plus macrolide + aminoglycoside (gentamicin, tobramycin, or amikacin)
References: [35, 36, 39, 40]
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317 Drug interactions between ART and CAP antibiotic thera-
318 py represent an important issue for clinicians. However, pen-
319 icillins, betalactam inhibitors, and levofloxacin do not interact
320 withART. For its part, moxifloxacin has a low interactionwith
321 atazanavir and lopinavir which are protease inhibitors. As
322 moxifloxacin has been shown to prolong the QT interval,
323 clinicians should exercise caution with its use, especially in
324 the case of patients with pre-existing risk factors (bradycardia,
325 long congenital QT, electrolyte imbalances). Caution is also
326 required in these patients regarding the use of azithromycin
327 since it may cause abnormal changes in the electrical activity
328 of the heart, and since the interactions between atazanavir,
329 lopinavir and saquinavir (protease inhibitors), and rilpivirine/
330 FTC/TAF (NNRTIS) are low.
331 Clarithromycin presents more drug interaction with all
332 classes of antiretrovirals (protease inhibitors, NNRTIS, entry
333 and integrase inhibitors, and nucleoside/tide analogues) be-
334 cause it can lead to a prolonged QT interval. In patients with
335 long QTsyndrome, cardiac disease, or in patients taking other
336 QT-prolonging medications, this can increase the risk of life-
337 threatening arrhythmias [49]. So the use of azithromycin is
338 preferred. For more information on drug-drug interaction,
339 consult
340 https://www.hiv-druginteractions.org/checker
341 Conclusions
342 Despite the advent of ART, pneumonia remains a major cause
343 of disease in the HIV-infected population. Pulmonary infec-
344 tions are also the main cause of ICU admission. Streptococcus
345 pneumoniae (pneumococcus) remains the most frequently de-
346 tected cause of CAP in HIV-positive/non-AIDS on ART. The
347 clinical presentation and management of CAP are similar in
348 HIV-infected patients on ART and in uninfected patients, and
349 outcomes in HIV virologically suppressed patients on ART
350 with > 350 CD4+ Tcell counts/mm3 are similar to those in the
351 general population. The general recommendation is that these
352 patients do not need special treatment, admission, or sites of
353 care. Treatment of HIV-positive/non-AIDS patients with CAP
354 is also similar to that in the general population and should
355 follow international guidelines.
356
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